17,261 trials
Sickle Cell Disease
Primary: Percentage of Participants With Two-Year Post-Transplant Event Free Survival (EFS) — 88.0; 79.3 Percentage of Participants
Chronic Hepatitis b
Primary: The Frequency and Severity of Treatment Emergent Adverse Events (TEAEs), Discontinuations Due to AEs and Lab Abnormalities After Dosing With AB-729 Plus Peg-IFNα-2a…
Immunoglobulin A (IgA) Nephropathy
Primary: Part 1: Relative Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) in 24-hour Urine at Month 9 — -24.7; -16.5; -30.6; -38.5 gram per gram (g/g) — p=0.6837
Essential Tremor of the Upper Limb
Primary: Unilateral Treatment Period: Change From Baseline to Week 6 in Maximum Tremor Amplitude of the Wrist — -0.25; -0.46 degrees of arc
Spinal Cord Injury
Primary: 10-meter Walking Speed (m/Sec) — 0.165; 0.215; 0.13; 0.13 speed (m/sec)
Restless Legs Syndrome · Augmentation
Primary: Change From Baseline (Predose) in Mean International Restless Legs Syndrome (IRLS) Rating Scale at End of Intervention Period — 20.6; 21.6; 16; 18.8 score on a scale
Allergic Rhinoconjunctivitis · Grass Pollen Allergy
Primary: TNSS Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour After the Challenge (0-1 Hour (hr) at Year 3 — 2.85; 3.61; 4.48 hr*TNSS — p=<0.001
Dry Eye Disease
Primary: Part 1: Number of Subjects With At Least One (1) Treatment-Emergent Adverse Event — 2; 1; 0; 2 Participants
Asthma in Children
Primary: Proportion of Patients Admitted to the Hospital in Each Group — 6; 15 Participants
Advanced Systemic Mastocytosis · Aggressive Systemic Mastocytosis · Systemic Mastocytosis With an Associated Hematologic Neoplasm
Primary: Overall Response Rate (ORR) Based on Modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on…
Acute Myeloid Leukemia
Primary: Feasibility of Successfully Generating CIML NK Cells With Standard of Care (SOC) DLI From the Original Stem Cell Donor as Measured by the Number of Participants That Had…
Contraception
Primary: Contraceptive Efficacy Through During LevoCept Use — 0; 0; 0 Pregnancies per 100 woman-years
RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy
Primary: Change in the Percentage of White Matter Hyperintensity (WMH) Lesion Volume on FLAIR MRI in RVCL Patients — 31.3 Percent (%)
Schistosomiasis · Schistosomiasis Mansoni · Schistosoma Japonicum Infection
Primary: Treatment Efficacy — 96; 98; 96; 98 percentage change
Hypertriglyceridemia · Atherosclerotic Cardiovascular Disease · Severe Hypertriglyceridemia
Primary: Percent Change From Baseline in Fasting TG at Month 6 — -7.77; -57.05; -60.92 Percent Change — p=<0.0001